M&A / Deals Novartis to acquire Myricx Bio in up to $1.5bn deal Pharmaceutical Business ReviewThe deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments.OncologyRead full story pharminent July 6, 2026 (Last updated: July 6, 2026) Pharmaceutical Business Review The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. Oncology Read full story Post navigation Previous: Roche looks to Astex in $515m breast cancer dealNext: Novartis Acquires UK ADC Specialist Myricx Bio for Up to $1.5 Billion Related Stories M&A / Deals Boehringer signs AI drug discovery deal with Owkin pharminent September 3, 2026 M&A / Deals Novartis signs $3.2bn drug delivery deal with Alteogen pharminent September 3, 2026 M&A / Deals Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology pharminent September 2, 2026